OMX Ventures

OMX Ventures is a venture capital firm dedicated to investing in the emerging field of bioengineering and its applications, including advanced tools, medicines, foods, and industrial products. The firm specializes in early-stage investments at the convergence of biology, big data, and AI, with a particular focus on therapeutics, biotechnological tools, diagnostics, and synthetic biology platforms. Their mission is to support groundbreaking discoveries and grow them into scalable companies, particularly in the fields of therapeutics, bio-tools, diagnostics, and synthetic biology.

The firm's strategy involves investing early to plant the seeds for successful company growth, building conviction and ownership in promising leaders through subsequent investments, and advising and guiding portfolio companies throughout their corporate life cycle. OMX Ventures' first fund, OMX Ventures Fund I, has raised more than $150 million in committed capital, which will be invested primarily in Seed and Series A investments. The firm aims to help founders build strong teams, overcome key technical challenges in their first two years of operations, and grow into successful commercial enterprises.

Before founding OMX, the partners invested early in successful biotech companies like 10X Genomics, Twist Bioscience, Ginkgo Bioworks, and QuantaLife (now part of Bio-Rad). Their experience and network in the biotech sector enable them to provide hands-on support to help founders secure milestones, establish strong intellectual property, and attract follow-on investor capital. OMX Ventures acts as a strategic partner deeply rooted in life sciences and intellectual property expertise, providing guidance on capital journey, company strategy, and future direction.